Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene

Lim, 2017, The principles of engineering immune cells to treat cancer, Cell, 168, 724, 10.1016/j.cell.2017.01.016

Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025

Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621

Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, J Clin Invest, 121, 1822, 10.1172/JCI46110

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842

Xu, 2014, Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15, Blood, 123, 3750, 10.1182/blood-2014-01-552174

Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540

Lamers, 2011, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells, Blood, 117, 72, 10.1182/blood-2010-07-294520

Maus, 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res, 1, 26, 10.1158/2326-6066.CIR-13-0006

Sommermeyer, 2017, Fully human CD19-specific chimeric antigen receptors for T-cell therapy, Leukemia, 31, 2191, 10.1038/leu.2017.57

Norelli, 2016, Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects, Biochim Biophys Acta, 1865, 90, 10.1016/j.bbcan.2015.12.001

Cruz, 2013, Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study, Blood, 122, 2965, 10.1182/blood-2013-06-506741

Jena, 2013, Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials, PLoS One, 8, e57838, 10.1371/journal.pone.0057838

Philip, 2014, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, 124, 1277, 10.1182/blood-2014-01-545020

Ciceri, 2009, Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study, Lancet Oncol, 10, 489, 10.1016/S1470-2045(09)70074-9

Yan, 1991, Disruption of cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding, J Biol Chem, 266, 12099, 10.1016/S0021-9258(18)99070-8

Riviere, 1995, Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells, Proc Natl Acad Sci U S A, 92, 6733, 10.1073/pnas.92.15.6733

Nijmeijer, 2001, Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice, Exp Hematol, 29, 322, 10.1016/S0301-472X(00)00669-X

Falcone, 2016, Exploiting Secreted luciferases to monitor tumor progression in vivo, Methods Mol Biol, 1393, 105, 10.1007/978-1-4939-3338-9_10

Casucci, 2013, CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma, Blood, 122, 3461, 10.1182/blood-2013-04-493361

Hombach, 2010, Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response, Gene Ther, 17, 1206, 10.1038/gt.2010.91

Hudecek, 2015, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol Res, 3, 125, 10.1158/2326-6066.CIR-14-0127

Almasbak, 2015, Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model, Gene Ther, 22, 391, 10.1038/gt.2015.4

Watanabe, 2016, Fine-tuning the CAR spacer improves T-cell potency, Oncoimmunology, 5, e1253656, 10.1080/2162402X.2016.1253656

Jonnalagadda, 2015, Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy, Mol Ther, 23, 757, 10.1038/mt.2014.208

Bonini, 2003, Safety of retroviral gene marking with a truncated NGF receptor, Nat Med, 9, 367, 10.1038/nm0403-367

Kaneko, 2009, IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes, Blood, 113, 1006, 10.1182/blood-2008-05-156059

Bondanza, 2011, IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors, Blood, 117, 6469, 10.1182/blood-2010-11-320366

Cieri, 2013, IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors, Blood, 121, 573, 10.1182/blood-2012-05-431718

Zheng, 2012, Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry, J Transl Med, 10, 29, 10.1186/1479-5876-10-29

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Ghosh, 2017, Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity, Nat Med, 23, 242, 10.1038/nm.4258

Brudno, 2016, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease, J Clin Oncol, 34, 1112, 10.1200/JCO.2015.64.5929

Liu, 2016, Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy, Nat Biotechnol, 34, 430, 10.1038/nbt.3461

Haso, 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121, 1165, 10.1182/blood-2012-06-438002

Guest, 2005, The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens, J Immunother, 28, 203, 10.1097/01.cji.0000161397.96582.59

Hudecek, 2010, The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor, Blood, 116, 4532, 10.1182/blood-2010-05-283309

Hudecek, 2013, Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells, Clin Cancer Res, 19, 3153, 10.1158/1078-0432.CCR-13-0330

Legras, 1998, A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia, Blood, 91, 3401, 10.1182/blood.V91.9.3401

Liebisch, 2005, CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q, Haematologica, 90, 489

Heider, 2004, CD44v6: a target for antibody-based cancer therapy, Cancer Immunol Immunother, 53, 567, 10.1007/s00262-003-0494-4

Zoller, 2011, CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?, Nat Rev Cancer, 11, 254, 10.1038/nrc3023

Jacoby, 2016, CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity, Nat Commun, 7, 12320, 10.1038/ncomms12320

Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547